Cardiol Therapeutics Inc.

TSX:CRDL Stok Raporu

Piyasa değeri: CA$180.3m

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Cardiol Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Cardiol Therapeutics' CEO'su David Elsley, Jan2017 tarihinde atandı, in görev süresi 7.75 yıldır. in toplam yıllık tazminatı CA$ 748.10K olup, şirket hissesi ve opsiyonları dahil olmak üzere 70.2% maaş ve 29.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.72% ine doğrudan sahiptir ve bu hisseler CA$ 3.24M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 2.8 yıldır.

Anahtar bilgiler

David Elsley

İcra Kurulu Başkanı

CA$748.1k

Toplam tazminat

CEO maaş yüzdesi70.2%
CEO görev süresi7.8yrs
CEO sahipliği1.7%
Yönetim ortalama görev süresi3.8yrs
Yönetim Kurulu ortalama görev süresi2.8yrs

Son yönetim güncellemeleri

Recent updates

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12
We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

May 01
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Jan 06
Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Sep 13
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

May 24
We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Jan 20
We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Aug 10
We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Apr 17
We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Dec 09
Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Aug 19
We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Apr 18
Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Jan 03
Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

CEO Tazminat Analizi

David Elsley'un ücretlendirmesi Cardiol Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-CA$29m

Mar 31 2024n/an/a

-CA$30m

Dec 31 2023CA$748kCA$525k

-CA$28m

Sep 30 2023n/an/a

-CA$28m

Jun 30 2023n/an/a

-CA$30m

Mar 31 2023n/an/a

-CA$29m

Dec 31 2022CA$654kCA$525k

-CA$31m

Sep 30 2022n/an/a

-CA$30m

Jun 30 2022n/an/a

-CA$32m

Mar 31 2022n/an/a

-CA$32m

Dec 31 2021CA$1mCA$455k

-CA$32m

Sep 30 2021n/an/a

-CA$35m

Jun 30 2021n/an/a

-CA$30m

Mar 31 2021n/an/a

-CA$27m

Dec 31 2020CA$517kCA$450k

-CA$21m

Sep 30 2020n/an/a

-CA$14m

Jun 30 2020n/an/a

-CA$13m

Mar 31 2020n/an/a

-CA$13m

Dec 31 2019CA$450kCA$450k

-CA$14m

Sep 30 2019n/an/a

-CA$20m

Jun 30 2019n/an/a

-CA$21m

Mar 31 2019n/an/a

-CA$19m

Dec 31 2018CA$713kCA$363k

-CA$16m

Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 554.49K ), Canadian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 177.89K ).

Tazminat ve Kazançlar: David şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

David Elsley

7.8yrs

Görev süresi

CA$748,100

Tazminat

Mr. David G. Elsley, MBA, has been the President, Chief Executive Officer and Director of Cardiol Therapeutics Inc since January 19, 2017. Mr. Elsley is a business leader with a proven track record of deve...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
David Elsley
President7.8yrsCA$748.10k1.72%
CA$ 3.1m
Christopher Waddick
CFO, Corporate Secretary & Director6.2yrsCA$294.80k0.16%
CA$ 283.8k
Bernard Lim
Chief Operating Officer3.8yrsCA$515.90k0.043%
CA$ 77.4k
Andrew Hamer
Chief Medical Officer & Head of Research & Development3.6yrsCA$746.56k0.45%
CA$ 811.1k
Trevor Burns
Investor Relationsno dataVeri yokVeri yok
John Geddes
Vice President of Corporate Developmentless than a yearVeri yokVeri yok

3.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: CRDL 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
David Elsley
President7.8yrsCA$748.10k1.72%
CA$ 3.1m
Christopher Waddick
CFO, Corporate Secretary & Director2.4yrsCA$294.80k0.16%
CA$ 283.8k
Colin Stott
Independent Director4.8yrsCA$60.00k0.20%
CA$ 367.7k
Jennifer Chao
Independent Director2.6yrsCA$76.92k0.14%
CA$ 258.0k
Peter Pekos
Independent Director6.8yrsCA$58.00k0.67%
CA$ 1.2m
Michael Willner
Independent Director3.1yrsCA$71.52k1.22%
CA$ 2.2m
Paul Ridker
Member of Scientific Advisory Board2.8yrsVeri yokVeri yok
Bruce McManus
Member of Scientific Advisory Board2.8yrsVeri yokVeri yok
Teri Loxam
Independent Director2.4yrsCA$82.32k0.17%
CA$ 309.6k
Guillermo Torre-Amione
Independent Chairman6.2yrsCA$112.68k0.32%
CA$ 568.9k
Joseph Hill
Member of Scientific Advisory Board2.8yrsVeri yokVeri yok

2.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CRDL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.